جستجوی مقالات مرتبط با کلیدواژه « G6PD » در نشریات گروه « پزشکی »

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is humans’ most common erythrocyte enzyme defect. About 400 million people are estimated to be affected by this disorder worldwide. Antimalarial drugs, especially primaquine, and other oxidative stress, can cause hemolytic complications in G6PD deficient individuals. This study aimed to evaluate the prevalence of G6PD deficiency in Kerman City in southern Iran.
This descriptive cross-sectional study was conducted from 2016 to 2021. Blood samples were taken from all patients with symptoms of G6PD deficiency who were referred to a general hospital in Kerman City in southern Iran. The G6PD enzyme activity was measured qualitatively by fluorescent spot test.
A total of 6369 patients were included in this study. G6PD deficiency was seen in 424 (6.7%) subjects. Of 424 patients, 359 (84.7%) were severely G6PD deficient, and 65 (15.3%) patients exhibited partial deficiency. G6PD deficiency was seen in 324 (9.3%) males and 100 (3.4%) females (p < 0.001).
The results of our study confirmed the existence of G6PD deficiency in a significant percentage of patients in Kerman City. Therefore, many people in this city are exposed to hemolytic complications if they use antimalarial drugs and other oxidative substances. According to our results, testing G6PD deficiency and monitoring the potential primaquine toxicity in patients who receive primaquine are highly recommended.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a global problem and the most common cause of jaundice in neonates. Hence, this study was conducted to investigate the prevalence of G6PD deficiency in Jiroft city in southern Kerman.

This descriptive cross-sectional study was carried out from 2016 to 2019. Blood samples were taken from all patients referred to Imam Hospital in Jiroft city in southern Iran. The G6PD enzyme activity was evaluated by a fluorescent spot test.

In the present study, a total of 7791 newborns were included. Abnormal activity of G6PD was seen in 779 (10%) subjects. Out of 779 patients, 728 (9.4%) were found to be G6PD deficient, and 49 (0.6%) exhibited partial deficiency. A relatively high percentage of G6PD deficiency was seen in newborns of Jirof city. We strongly recommend screening for G6PD enzyme activity in all newborns in this city.

The aim of this study was to perform a systematic review and meta-analysis on available data about glucose-6-phosphate dehydrogenase enzyme deficiency (G6PDD) status in Iranian neonates screened for the disease.

A literature search was conducted in electronic databases of Embase, PubMed, Web of Sciences, Scopus and Google Scholar for articles published from inception to 1 December 2018. Moreover, the literatures from Iranian databases, including Magiran and Scientific Information Database were searched. We included observational studies reporting prevalence of G6PDD, related complications and genetic factors among Iranian neonates. Data were analyzed using STATA software.

Of 656 articles were initially found, 16 were finally included. Overall pooled prevalence of G6PDD was 5.5% (95% confidence interval: 2-8.9). Analysis also indicated that boys were significantly 3 times more at risk of G6PDD compared with girls. Three articles were identified related to the jaundice and 4 papers related to kernicterus. A range of 43-67% of newborns with G6PDD presents with jaundice. Additionally, 5-9% of G6PDD cases with jaundice present with kernicterus. One article reported that out of 412 newborns, 12.9% were carriers for one of the three G6PD gene mutations, including Mediterranean, Chatham and Cosenza.

Prevalence of G6PDD in Iran is comparable to most countries. Jaundice and kernicterus are major complications of G6PDD. Therefore, it is necessary to pay attention to all patients with G6PDD. Also, it is recommended that hospitals provide the result of G6PD testing as soon as possible and before discharging newborn children.

This study aimed to investigate the frequency of Q192R polymorphism and oxidative stress markers in infants with glucose-6-phosphate dehydrogenase (G6PD) deficiency.

This is a case-control study in which 60 male infants (2-4 months old) with G6PD deficiency along with 60 age- and sex-matched healthy neonates were included. The diagnosis of G6PD deficiency was made by Beutler test by which the G6PD enzyme activity is measured by the fluorescent spot test. The blood samples were taken from all infants, and the sera were isolated for the evaluation of Paraoxonase-1 (PON1) and malondialdehyde (MDA) using the spectrophotometric method. Restriction fragment length polymorphism was applied for determination of Q192R polymorphism (rs 662).

The frequencies of QQ, QR, and RR genotypes were 55%, 39%, and 6%, respectively in infants with G6PD deficiency while the above genotype frequencies were 45%, 49%, and 6%, respectively in healthy neonates. The frequency of R and T alleles failed to show any significant difference when G6PD deficient infants and healthy neonates were compared. The results indicated PON1 activity and MDA levels being significantly (p<0.05) higher in neonates with G6PD deficiency compared with their healthy counterparts.

Contrary to previous studies, it was indicated that the presence of RQ and RR genotypes at Q192R position is associated with decreased activity of PON1 and increased oxidative stress. In this study, no significant differences were found in the genotype and allele frequency of PON1 Q192R polymorphism between the case and control groups. Also, this frequency was not consistent with the results obtained from oxidative stress conditions.

Glucose-6-phosphate dehydrogenase deficiency (G6PD) or fauvism is the most common enzyme deficiency in human, so that 400 million people are living with this disease worldwide. This study aimed to investigate the role of some neonatal factors among newborns suffering from G6PD deficiency and neonatal outcomes associated with this disease.

In this study, two methods including case-control and retrospective cohort regarding some neonatal factors associated with G6PD deficiency were used. These methods were performed on 142 children with this kind of deficiency and 142 healthy infants in the city of Marvdasht during 2013- 2014. The analysis of data was based on chi-square tests, t-test, logistic regression, descriptive statistics and estimation of odds ratios or relative risks via SPSS16 software.

Totally 284 newborns including 132 (46.6%)/ 152 (53.4%) boys/girls and mean weight on birth of 3163 ± 471 (gr) were analyzed. Comparison of case and control samples did not show any significant differences between sex and involving with G6PD deficiency but the chance of having a baby with this defect in pregnancy intervals between 6 to 8 years was increased (95% CI: 1- 4.4, OR: 2). Relative risk of jaundice in infected and healthy infants was estimated as 3.73, which demonstrated a statistically significant association (95% CI: 1.33- 10.4). The frequency of low birth weight, birth order and type of delivery was associated with the disease, but their differences were insignificant compared to the healthy group.

The results of this study showed that the number of hospitalization is increased due to jaundice in infants with G6PD. There is also an insignificant relation between low birth weight, rank of birth and type of delivery. Thus, it is recommended that other consequences of this deficiency need to be revealed by screening other populations with more samples.

Irish potatoes is rich in carbohydrate, with varied glucose levels. It is also a very good source of apyrase, an enzyme used for platelet storage. The aim of this study was to explore Irish potatoes as an easily available source for apyrase extraction and purification. Apyrase was extracted from 5 Kg of Irish potatoes. Platelets were derived from 5-10 ml of human whole blood and G6PD activity was assessed in platelets stored for 48 h either in presence or absence of apyrase (commercial or extracted from Irish potatoes) using fluorescent spot test and electrophoresis. Platelets stored in apyrase showed G6PD activity under both fluorescent spot test and electrophoresis method, whereas those stored without apyrase enzyme for such a time did not show G6PD activity. Therefore, potatoes could be used as a valuable source for preparing apyrase and allowing platelet storage for long duration for in vitro studies or transfusion purposes, especially in bleeding disorders which will be complicated without adequate conservative medium, due particularly to the short half life of this blood cell.

Sodium bicarbonate serum therapy is used for compensation bicarbonate lost and increasing blood pH in metabolic acidosis caused by severe anemia in patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The aim of present study was comparison the effect of serum therapy using two different serums (serum with bicarbonate and without bicarbonate) on some renal and hematologic factors and their side effects in patients with hemolysis caused by G6PD deficiency.
In this clinical trial study, 79 patients with favism randomly put into two treatment groups, sodium bicarbonate and sodium chloride fluid therapy. During treatment, patients received blood based on hemoglobin (Hb). Duration of hospitalization, times of Blood transfusion, received blood volume, duration of cleaning UA of Hb, Hb, urine pH and granular casts in UA were evaluated.
The mean age of patients was 51.22 ± 37.86 months and there were 58 males and 21 females. Only duration of hospitalization and urine pH statistically showed a significant difference between two treatment groups (P=0.036 and P> 0.01, respectively), and other factors were statistically almost identical.
The efficiency of sodium chloride was more than sodium bicarbonate in reducing the duration of hospitalization and the small clinical difference between received blood volumes, hemoglobin changes and duration of removing hemoglobin in UA, suggest, properly, sodium chloride can be more effective on improvement of hemolysis. Lack of side effects such as metabolic acidosis, heart damage and kidney failure in children can be due to controlled injection method, the concentration of soluble drugs and small size of studied population.

Search results show that numerous primary studies have been carried out in different parts of Iran regarding prevalence of G6PD deficiency; if results of these studies are combined, a reliable estimation of prevalence of this factor will be achieved in Iran. Thus, present study, aimed to determine the prevalence of G6PD deficiency by combining findings of qualified primary studies using meta-analysis and taking into account heterogeneity considerations. Searching the relevant keywords in Iranian and International databases, primary studies were selected. After quality appraisal and applying inclusion and exclusion criteria, relevant primary studies were selected. In each study, standard error of prevalence of G6PD was calculated according to binominal distribution formula. Finally, heterogeneity index was determined among studies using Cochran's test. Prevalence of G6PD in Iran was estimated by STATA software ver 11 using fixed or random effect model based on heterogeneity results. 148916 subjects in 36 primary studies which entered this meta-analysis were examined. G6PD deficiency prevalence was 6.7% in Iran (men: 8.8% and women: 2.2%). Also, this deficiency in the present study was four times higher in men than in women. Its prevalence was adjusted in different parts of Iran and it was shown that it was between 0.8 and 15.2 using Bayesian analysis. This meta-analysis showed that Iran is among countries with high frequency of G6PD deficiency and there is a significant difference in prevalence of G6PD in different parts of Iran. According to these results, screening newborn children seems very vital. Carrying out other primary studies regarding prevalence of G6PD seems unnecessary.

Glucose-6-phosphate dehydrogenase (G6PD) enzyme deficiency is one of the prevalent disorders in Guilan province, northern Iran, causing many patients to suffer from acute hemolysis. This disease has imposed tremendous costs both on patients and Health systems.The aim of this study was to compare the direct costs of favism treatment on patients and health system with G6PD enzyme screening test. In this descriptive prospective study, the medical and hospital costs of acute hemolysis due to G6PD deficiency were calculated and compared with the expenses of screening newly born infants for this disorder in Rasht. Data was collected by a questionnaire.Student’s t-Test and chi-squared test were recruited and data was analyzed using SPSS ver. 20. In this study, 101 hospitalized patients with favism (72 male and 29 female) admitted from October 2011 to the end of September 2012 were included. The average cost of treatment for these patients was approximately 726000000Rials (for each patient 7190000 Rials), which was about half of the cost of screening for all newborn infants in Rasht during this period. The cost of G6PD enzyme screening in Rasht is substantially lower than the cost of treating hospitalized patients with Favism.

Glucose-6-phosphate dehydrogenase is one of the most common genetic deficiencies, which approximately 400 million people in the world suffer from. According to authors'' initial search, numerous studies have been carried out in Iran regarding molecular variants of this enzyme. Thus, this meta-analysis presented a reliable estimation about prevalence of different types of molecular mutations of G6PD Enzyme in Iran. Keywords «glucose 6 phosphate dehydrogenase or G6PD, Mediterranean or Chatham or Cosenza and mutation, Iran or Iranian and their Persian equivalents» were searched in different databases. Moreover, reference list of the published studies were examined to increase sensitivity and to select more studies. After studying titles and abstracts of retrieved articles, excluding the repeated and unrelated ones, and evaluating quality of articles, documents were selected. Data was analyzed using STATA. After performing systematic review, 22 papers were entered this meta-analysis and 1698 subjects were examined concerning G6PD molecular mutation. In this meta-analysis, prevalence of Mediterranean mutation, Chatham mutation and Cosenza mutation in Iran was estimated 78. 2%, 9. 1% and 0. 5% respectively. This meta-analysis showed that in spite of prevalence of different types of G6PD molecular mutations in center, north, north-west and west of Iran, the most common molecular mutations in people with G6PD deficiency in Iran, like other Mediterranean countries and countries around Persian Gulf, were Mediterranean mutation, Chatham mutation and Cosenza mutation. It is also recommended that future studies may focus on races and regions which haven''t been taken into consideration up to now.

G6PD deficiency is the most common enzymopathy of red blood cells. The clinical symptoms of favism are jaundice, hematuria and haemolytic anaemia that seem to affect liver and kidney in long term. Thus we evaluate kidney and liver function of favism patients in an endemic area of the disease with a high rate of fava beans cultivation. This study was performed on favism patients and healthy controls referring to Iranshahr central hospital. Liver and kidney function tests were performed. The results showed a statistically significant difference between these two groups (p <0.05) for liver function tests, (AST, ALT and ALP), but not for renal tests (BUN and creatinine) (p >0.05). Due to abnormalities were seen in the liver function tests of these patients, we suggest that these tests be regularly performed for favism patients who are constantly exposed to oxidant agents.